Premium Industrial News

China's CARsgen Joins European Plan for Tumor Therapy

China's CARsgen Joins European Plan for Tumor Therapy

pharmaceutical

Industry Segment: Pharmaceutical & Biotech | Word Count: 119 Words

BEIJING--November 24, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical company CARsgen Therapeutics Holdings Limited (Xuhui, China) recently joined European Medicines Agency's (EMA) PRIME (Priority Medicine) plan for its CAR-T Therapy product CT041, which is used to treat solid tumors.

This Premium Article can be purchased individually or as part of a subscription

Subscribe Now!(All Fields Required)

Subscription Type:

  • Pay-Per-Article - $5.95
  • Annual Premium News Subscription - $365.00
Pricing Help?